One pathway is CAR T 5T4 which I believe that Oxford BioMedica is working without Novartis. See page 10 at the following link.
http://www.oxfordbiomedica.co.uk/uploads/corporate-presentation/oxb-jefferies-conf-ny-june16-csc.pdf
The other pathway for using CART to treat solid tumors Oxford BioMedica is working with and under the direction of Novartis and the University of Pennsylvania.
Novartis (CTL-019 and other undisclosed CAR-T programme) see page 7 at the link.
That undisclosed CAR-T programme is I believe based on the "Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells"
Good luck and GOD bless,
George
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM